Inhibitory Properties of Tumor Growth by Quercetin in Xenograft ModelsInhibitory Properties of Tumor Growth by Quercetin in Xenograft Models
- Other Titles
- Inhibitory Properties of Tumor Growth by Quercetin in Xenograft Models
- Authors
- 이윤경; 이원섭; 이희구; 황진택; 박옥진; 신장인
- Issue Date
- 2009
- Publisher
- 대한암예방학회
- Keywords
- Quercetin; AMP-activated protein kinase; Akt; Cyclooxygenase-2; MCF-7 xenograft
- Citation
- 대한암예방학회지, v.14, no.1, pp 54 - 59
- Pages
- 6
- Indexed
- KCI
- Journal Title
- 대한암예방학회지
- Volume
- 14
- Number
- 1
- Start Page
- 54
- End Page
- 59
- URI
- https://scholarworks.gnu.ac.kr/handle/sw.gnu/26962
- ISSN
- 2288-3649
2288-3657
- Abstract
- Quercetin is a flavonoid found in many fruits, vegetables and tea and exerts anti-tumor activity in several tumor models. In this study, we have examined the tumor growth inhibitory effect of quercetin in MCF-7 xenograft models using female and male mice and observed alteration of signaling molecules involved in cell survival and apoptosis. Our results showed that administration of 50μg/g quercetin daily significantly inhibited tumor growth in both female and male MCF-7 xenograft models. It has shown that quercetin increases the activation of AMP-activated protein kinase (AMPK) along with tumor regression. AMPK is a major signaling molecule for the regulation of energy metabolism. Recent studies indicated that AMPK acts as a master controller in cancer cells through regulating several survival-related pathways. Phosphorylated Akt and Cycloxygenase-2 (COX-2) levels were found to be related to anti-tumor activities of quercetin. The results suggested that quercetin has a potential anti-tumor activity against breast cancer and it may be related to suppression of oncogenic molecules such as Akt and COX-2, and activation of pro-apoptotic molecules such as AMPK.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medicine > Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.